Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout

Group 1 - ABIVAX is recognized as a promising emerging technology stock, with Guggenheim analyst Yatin Suneja raising the price target from $150 to $175, maintaining a Buy rating due to an optimistic outlook for obefazimod [1] - In Q3 2025, ABIVAX reported revenues of $2.40 million, exceeding estimates by $1.06 million, but incurred a loss per share of $1.68, with a net loss for the first nine months of €254.1 million, up from €136.9 million in 2024 [2] - R&D expenses increased to €133.4 million, driven by the ABTECT Phase 3 program for ulcerative colitis and the ENHANCE-CD Phase 2b trial for Crohn's disease, with key milestones expected in 2026 [3] Group 2 - ABIVAX is a clinical-stage biotechnology company focused on developing therapeutics that stabilize the immune response in patients with chronic inflammatory diseases [4]